Physician profile
Mario Ceja
NPI 1891753315
$1,083.25
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $218 · 2021: $158 · 2022: $120 · 2023: $34.67 · 2024: $30.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $236.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $210.36 | 2019-2020 | |
| Abbvie INC. | $107.65 | 2021-2024 | |
| Amgen INC. | $103.22 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.72 | 2022 | |
| Merck Sharp & Dohme LLC | $39.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.36 | 2019 | |
| Pfizer INC. | $37.33 | 2019 | |
| Abbott Laboratories | $28.58 | 2019-2023 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $27.75 | 2019 | |
| Novo Nordisk INC | $24.26 | 2020-2021 | |
| Neotract INC. | $23.37 | 2019 | |
| Corcept Therapeutics | $23.29 | 2021 | |
| Glaxosmithkline, LLC. | $22.11 | 2019 | |
| Ironwood Pharmaceuticals, INC | $20.48 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.13 | 2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $19.05 | 2020 | |
| Astellas Pharma US INC | $16.45 | 2019 | |
| Phadia US INC. | $14.35 | 2019 | |
| Amarin Pharma, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Ceja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.